

## ASX Release

### Anatara General Meeting Results

MELBOURNE, 12 December 2022: Anatara Lifesciences (ASX: ANR), is pleased to announce the following results from the General Meeting held on 12 December 2022.

At today's General Meeting all Resolutions put to Shareholders were passed on a poll. Details of the Proxy Votes are attached.



**STEPHEN DENARO**  
**COMPANY SECRETARY**

This announcement is authorised by the Board, Anatara Lifesciences Limited.

**--Ends--**

#### **For more information please contact:**

Dr. David Brookes  
Chair, Anatara Lifesciences Ltd  
Ph: +61 (0) 411 712 579 Email: [dbrookes@anatara.com](mailto:dbrookes@anatara.com)

Alastair Murray  
Candour Advisory Pty Ltd  
Investor Relations  
PH: +61 (0) 415 629 977 Email: [alastair@candouradvisory.com.au](mailto:alastair@candouradvisory.com.au)

#### **About Anatara Lifesciences Ltd**

Anatara Lifesciences Ltd (ASX: ANR) is developing and commercialising innovative, evidence-based solutions for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

#### **Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of Tranche 1 Placement Shares	Ordinary	10,957,431 99.62%	37,000 0.34%	4,000 0.04%	10,000	10,961,431 99.66%	37,000 0.34%	10,000	Carried
2 Authority to issue Tranche 1 Placement Options	Ordinary	10,957,431 99.62%	37,000 0.34%	4,000 0.04%	10,000	10,961,431 99.66%	37,000 0.34%	10,000	Carried
3 Authority to issue Tranche 2 Placement Shares	Ordinary	22,619,007 99.82%	37,000 0.16%	4,000 0.02%	10,000	22,623,007 99.84%	37,000 0.16%	10,000	Carried
4 Authority to issue Tranche 2 Placement Options	Ordinary	22,619,007 99.82%	37,000 0.16%	4,000 0.02%	10,000	22,623,007 99.84%	37,000 0.16%	10,000	Carried
5 Issue of Tranche 2 Placement Shares and Tranche 2 Placement Options to a Related Party – Dr David Brookes	Ordinary	22,802,085 99.82%	37,000 0.16%	4,000 0.02%	460,000	22,806,085 99.84%	37,000 0.16%	460,000	Carried
6 Issue of Tranche 2 Placement Shares and Tranche 2 Placement Options to a Related Party – Dr Jane Ryan	Ordinary	23,069,007 99.82%	37,000 0.16%	4,000 0.02%	193,078	23,073,007 99.84%	37,000 0.16%	193,078	Carried
7 Authority to issue Advisor Options	Ordinary	12,265,453 52.65%	11,023,632 47.33%	4,000 0.02%	10,000	12,269,453 52.67%	11,023,632 47.33%	10,000	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.